Print Page  |  Close Window

2017 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
09/20/2017OpGen to Present at the Ladenburg Thalmann 2017 Healthcare Conference
GAITHERSBURG, Md., Sept. 20, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that Evan Jones, the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 4:00 p.m. Eastern time. The conference is being held that day at the Sofitel Hotel in New York City. To listen to the presentation live, investors may visit the investor relations section of OpGen, Inc.’s webs... 
 Printer Friendly Version
09/08/2017OpGen Data on New Rapid Gene Test and Antibiotic Susceptibility Prediction Algorithms Presented at the 2017 ASM/ESCMID Conference
GAITHERSBURG, Md., Sept. 08, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that the Company presented study results on the company’s new rapid test in development, the Acuitas® AMR Gene Panel u5.47, and the Acuitas Lighthouse® Knowledgebase for prediction of antibiotic susceptibility at the 2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. The poster presentation, titled “Predicting Antibiotic Resistance in Gram-Negative Baci... 
 Printer Friendly Version
09/06/2017OpGen to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 06, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that Evan Jones, the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 12:05 p.m. Eastern time. The conference is being held on September 10-12, 2017 at the Lotte New York Palace Hotel. To listen to the presentation live, investors may visit the investor relations ... 
 Printer Friendly Version
08/08/2017OpGen Reports 2017 Second Quarter Financial Results and Provides Business Update
Affirms plans to launch first Acuitas® Rapid Test in first half of 2018 Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., Aug. 08, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) reports financial and operational results for the three and six months ended June 30, 2017, and provides a summary of recent business highlights. “During the second quarter and recent weeks we achieved important milestones in the development of our first Acuitas® Rapid Test and the Acui... 
 Printer Friendly Version
08/02/2017OpGen Announces Date of Second Quarter 2017 Financial Results Conference Call
GAITHERSBURG, Md., Aug. 02, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its second quarter 2017 financial results after close of market on Tuesday, August 8, 2017. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and business progress. Dial-in Information U.S. Dial-In Number: (888) 883-4599 International Dial-In Number: (484) 653-6821 Conference ID: 61883667... 
 Printer Friendly Version
07/19/2017OpGen Announces Closing of $10 Million Public Offering
GAITHERSBURG, Md., July 19, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the closing of its previously announced public offering of 18,164,195 units at $0.40 per unit, and 6,835,805 pre-funded units at $0.39 per pre-funded unit, raising gross proceeds of approximately $10 million. The Company intends to use the net proceeds of this offering for general corporate purposes, including working capital and product development, particularly development of its rapid antibiotic resista... 
 Printer Friendly Version
07/13/2017OpGen Announces Pricing of $10.0 Million Public Offering
GAITHERSBURG, Md., July 13, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the pricing of a public offering of an aggregate of 25,000,000 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share of common stock. The units are being offered at a price of $0.40 per unit. Each common warrant has an exercise price of $0.425 per share, is exercisable immediately and will expire five years from the date of i... 
 Printer Friendly Version
07/12/2017OpGen Acuitas® MDRO Gene Test Approved by NY State Department of Health
GAITHERSBURG, Md., July 12, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the New York State Department of Health (NYSDOH) has approved the Acuitas® MDRO Gene Test for use by physicians and healthcare providers in the state. The approval of OpGen’s CLIA laboratory to perform testing in New York State includes approval for the complete OpGen MDRO testing workflow, including MDRO gene testing on perianal swabs and clinical isolates. The NYSDOH regulates and oversees cli... 
 Printer Friendly Version
06/19/2017OpGen Signs Supply Agreement to Use Thermo Fisher Scientific’s Technology to Advance Acuitas® Rapid Test
GAITHERSBURG, Md., June 19, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it has entered into a global supply agreement to use Thermo Fisher Scientific’s technology to support the commercialization of its rapid molecular products and informatics system to help combat multidrug-resistant infections. OpGen will combine Thermo Fisher’s real-time PCR solutions with its genomic analysis and bioinformatics technology to help healthcare providers rapidly and accurately ident... 
 Printer Friendly Version
06/15/2017OpGen’s Acuitas® Detection Technology Utilized in Publication Revealing Prevalence of CRE in Washington D.C. Healthcare Facilities
Results of over 1,000 patient samples for antibiotic resistant bacteria published today in Infection Control & Hospital Epidemiology GAITHERSBURG, Md., June 15, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced the publication of a citywide evaluation of Washington, D.C.’s healthcare facilities to gauge the prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) throughout the District of Columbia. OpGen’s Acuitas DNA tests and Acuitas Lighthouse® bioinformatics were ... 
 Printer Friendly Version
06/05/2017OpGen Data at ASM Microbe 2017 Demonstrates Potential of Acuitas Products for Predicting Antibiotic Susceptibility and Infection Control
GAITHERSBURG, Md., June 05, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced the results from additional studies supporting the capabilities of its Acuitas Rapid Test and Acuitas Whole Genome Sequence Analysis to accurately predict antibiotic resistance and for infection control. The results of these studies were presented in poster presentations at ASM Microbe 2017 in New Orleans, LA. The first poster, titled “Predicting Antibiotic Resistance in Gram-Negative Bacilli by R... 
 Printer Friendly Version
05/30/2017OpGen to Receive Ignaz Semmelweis Award for Commitment to Combatting Infection Deaths
GAITHERSBURG, Md., May 30, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that they will be recognized with the 2nd annual Ignaz Semmelweis Award for their commitment to safe medical care through the development of rapid diagnostics to combat multi-drug resistant infections. This award is handed out annually by the Committee to Reduce Infection Deaths (RID). “On behalf of our employees and our scientific collaborators, we are honored to be recognized by RID for our innov... 
 Printer Friendly Version
05/25/2017OpGen to Present Advancements in Antibiotic Susceptibility and Whole Genome Sequencing at ASM Microbe 2017
GAITHERSBURG, Md., May 25, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas® Rapid Test in development and Acuitas Whole Genome Sequence Analysis will be presented at ASM Microbe 2017 being held June 1-5, 2017 in New Orleans, LA. These data will demonstrate the company’s ability to predict phenotypic resistance across antibiotic classes for Gram-negative infections using rapid genetic testing and predictive algorithms from its Acuitas Lighthouse® Know... 
 Printer Friendly Version
04/27/2017OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors
GAITHERSBURG, Md., April 27, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that Tina S. Nova, Ph.D. has been appointed to its Board of Directors.   Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She currently serves as president and chief executive officer of Molecular Stethoscope, Inc., a newly formed molecular diagnostics company. Most recently, she was senior vice president and general manag... 
 Printer Friendly Version
04/26/2017OpGen Announces 2017 First Quarter Financial Results
GAITHERSBURG, Md., April 26, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operational results for the first quarter ended March 31, 2017 and summarized recent business highlights. “In the first quarter, we presented preliminary results supporting the Acuitas® Rapid Test in development for detection of resistance genes in multi-drug resistant pathogens and demonstrated the bioinformatics capabilities of the Acuitas Lighthouse® Knowledgebase to predict antib... 
 Printer Friendly Version
04/25/2017OpGen Highlights Capabilities of its Acuitas® Technologies to Rapidly Predict Antibiotic Susceptibility Using Drug Resistance Gene Profiles at ECCMID
GAITHERSBURG, Md., April 25, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has presented preliminary results supporting its Acuitas Rapid Test in development to detect antibiotic resistant genes and the use of predictive algorithms from its Acuitas Lighthouse® Knowledgebase to predict antibiotic susceptibility. The results were presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria. The poster, titled... 
 Printer Friendly Version
04/19/2017OpGen Announces Date of First Quarter 2017 Financial Results Conference Call
GAITHERSBURG, Md., April 19, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its first quarter 2017 financial results after close of market on Wednesday, April 26, 2017. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company’s financial results and business progress. Dial-in Information U.S. Dial-In Number: 844-420-8185 International Dial-In Number: 216-562-0481 Conference ID: 11373581 ... 
 Printer Friendly Version
04/13/2017OpGen to Present Antibiotic Resistance Prediction Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GAITHERSBURG, Md., April 13, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that five posters featuring its technologies will be presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 22-25, 2017 in Vienna, Austria. Among them will be a poster presentation titled "Prediction of antibiotic resistance in Escherichia Coli from resistance genes" by Dr. Terry Walker, Senior Vice President of Research and Development at Op... 
 Printer Friendly Version
04/13/2017OpGen to Present Antibiotic Resistance Prediction Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GAITHERSBURG, Md., April 13, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that five posters featuring its technologies will be presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 22-25, 2017 in Vienna, Austria. Among them will be a poster presentation titled “Prediction of antibiotic resistance in Escherichia Coli from resistance genes” by Dr. Terry Walker, Senior Vice President of Research and Development at ... 
 Printer Friendly Version
03/23/2017OpGen Announces 2016 Fourth Quarter and Year End Financial Results
Achieves Revenue of Approximately $4.0 Million, a 27% Year Over Year Increase GAITHERSBURG, Md., March 23, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operational results for the fourth quarter and year ended December 31, 2016 and summarized 2016 business highlights.  Total revenue for the full year ended December 31, 2016 was $4.0 million, a 27% increase from $3.2 million recorded for the full year ended December 31, 2015.  Net loss for the full year ended... 
 Printer Friendly Version
03/16/2017OpGen Announces Date of 2016 Fourth Quarter and Year End Financial Results Conference Call
GAITHERSBURG, Md., March 16, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its 2016 fourth quarter and year end financial results after close of market Thursday, March 23, 2017. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company’s financial results and recent developments. Dial-in Information U.S. Dial-In Number: 844-420-8185 International Dial-In Number: 216-562-0481 Conference ID... 
 Printer Friendly Version
03/01/2017OpGen to Present at the Cowen and Company 37th Annual Health Care Conference
GAITHERSBURG, Md., March 01, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that Evan Jones, the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Cowen and Company Health Care Conference on Tuesday, March 7, 2017 at 10:40 a.m. Eastern time. The conference is being held from March 6-8 in Boston, MA. To listen to the presentation live, investors may visit the investor relations section of OpGen, Inc.’s website at www.opgen.com. An ar... 
 Printer Friendly Version
02/14/2017OpGen Presents Rapid Acuitas Genetic Test Data at Advances in Genome Biology and Technology Meeting
Data support ability to predict antibiotic susceptibility in hours instead of days GAITHERSBURG, Md., Feb. 14, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced preliminary data demonstrating the ability to rapidly and accurately predict bacterial antibiotic susceptibility using resistance gene profiles. The data were presented at the Advances in Genome Biology and Technology (AGBT) meeting, which is taking place from February 13-16, 2017 in Hollywood Beach, FL. These prelimi... 
 Printer Friendly Version
01/26/2017OpGen Reports Preliminary Fourth Quarter and Full Year 2016 Financial Results
Achieves Revenue of Approximately $4.0 Million, a 27% Year Over Year Increase GAITHERSBURG, Md., Jan. 26, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2016, and summarized 2016 business highlights.  Total revenue for the full year ended December 31, 2016 was approximately $4.0 million, a 27% increase from the $3.2 million recorded for the full year ended December 31, 2015. Total revenue... 
 Printer Friendly Version